1116136-36-7

Usage

Uses

Used in Pharmaceutical and Agrochemical Synthesis:
1H-Pyrrolo[3,2-b]pyridine is used as a key building block for the development of various pharmaceuticals and agrochemicals due to its unique fused ring structure and nitrogen-containing aromatic properties, which contribute to the desired biological activities of the final products.
Used in Organic Electronics:
1H-Pyrrolo[3,2-b]pyridine... is utilized in the field of organic electronics, where its aromatic and electronic properties are harnessed to improve the performance of electronic devices, such as organic light-emitting diodes (OLEDs) and organic field-effect transistors (OFETs).
Used as a Fluorescent Probe in Biochemistry:
1H-Pyrrolo[3,2-b]pyridine is employed as a fluorescent probe for studying the structure and function of nucleic acids and proteins. Its fluorescent properties allow for the visualization and analysis of biomolecular interactions, providing valuable insights into biological processes.
Used in Enzyme Inhibition and Receptor Modulation:
1H-Pyrrolo[3,2-b]pyridine... is used as an inhibitor of certain enzymes and as a modulator of specific receptors in the central nervous system. Its ability to interact with these biological targets makes it a promising candidate for the development of drugs targeting neurological disorders and other conditions.
Used in Anticancer and Antiviral Research:
1H-Pyrrolo[3,2-b]pyridine derivatives are studied for their potential anticancer and antiviral activities. Their ability to interfere with cancer cell growth and viral replication processes positions them as promising agents for the development of novel therapeutics in oncology and virology.

Upstream product

• 272-49-1 1H-pyrrolo[3,2-b]pyridine 

Downstream Products

• 1190320-73-0 1H-pyrrolo[3,2-b]pyridine-7-carbonitrile 
• 1190319-05-1 3-iodo-1H-pyrrolo[3,2-b]pyridine-7-carbonitrile 
• 1547041-34-8 7-chloro-1-methyl-1H-pyrrolo[3,2-b]pyridine 

Relevant academic research and scientific papers

EIF4E-INHIBITING 4-OXO-3,4-DIHYDROPYRIDO[3,4-D]PYRIMIDINE COMPOUNDS

The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. For Formula I compounds X1, X2, X3, X4, X5, X6, Q, L1, L2, Y, R1, R2, R3, R4, R5, R6, R7, R8 and rings A, B and C are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4e and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.

BIARYL KINASE INHIBITORS

The present disclosure is directed to biaryl compounds of formula (I) which can inhibit AAKl (adaptor associated kinase 1), compositions comprising such compounds and their use for treating e.g. pain, Alzheimer's disease, Parkinson's disease and schizophrenia.

4-Azaindole Derivatives

4-Azaindole derivatives which are modulators of muscarinic acetylcholine receptor (mAChR) M1 and which may be effective for the prevention or disease modifying or symptomatic treatment of cognitive deficits associated with neurological disorders such as Alzheimer-type dementia (AD) or dementia with Lewy bodies (DLB), and a pharmaceutical composition comprising a 4-azaindole derivative as an active ingredient.

4-AZAINDOLE DERIVATIVES

4-Azaindole derivatives which are modulators of muscarinic acetylcholine receptor (mAChR) M1 and which may be effective for the prevention or disease modifying or symptomatic treatment of cognitive deficits associated with neurological disorders such as Alzheimer-type dementia (AD) or dementia with Lewy bodies (DLB), and a pharmaceutical composition comprising a 4-azaindole derivative as an active ingredient.

Lead optimization of 1,4-azaindoles as antimycobacterial agents

In a previous report, we described the discovery of 1,4-azaindoles, a chemical series with excellent in vitro and in vivo antimycobacterial potency through noncovalent inhibition of decaprenylphosphoryl-β-d-ribose-2′- epimerase (DprE1). Nevertheless, high mouse metabolic turnover and phosphodiesterase 6 (PDE6) off-target activity limited its advancement. Herein, we report lead optimization of this series, culminating in potent, metabolically stable compounds that have a robust pharmacokinetic profile without any PDE6 liability. Furthermore, we demonstrate efficacy for 1,4-azaindoles in a rat chronic TB infection model. We believe that compounds from the 1,4-azaindole series are suitable for in vivo combination and safety studies.

3' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY

The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I): wherein Q, R1, R4, m and Ar are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.